Etravirine vs Tenofovir alafenamide/emtricitabine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Etravirine · Intelence

Marketed by Johnson & Johnson

Approved in HIVsmall molecule
Reliable signal

NCT00254046 · Phase 3 · completed

Participants were randomized and blinded to etravirine or placebo on top of background therapy. A significantly larger share of patients on etravirine achieved viral suppression than on placebo.

Reported efficacy

Evaluation of efficacy, tolerability and safety of TMC125 as part of an antiretroviral therapy containing TMC114/ritonavir and an investigator selected optimized background regimen. (24 weeks): Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005 (met)

Result source: NCT00254046

Tenofovir alafenamide/emtricitabine · Descovy

Marketed by Gilead Sciences

Approved in HIVsmall molecule combination
Reliable signal

NCT02121795 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled trial of 668 participants, with 333 receiving F/TAF and 330 receiving FTC/TDF in the treated analysis. The primary clinical endpoint was met: virologic suppression was 94.3% versus 93.0%, and the prespecified non-inferiority confidence interval remained within the 10% margin.

Next expected readout: January 2027 · NCT07349758 (registry estimate)

Reported efficacy

Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Descovy (DVY) 0.16 HIV-1 infections per 100 PY (95% CI 0.064 to 0.33) | Truvada (TVD) 0.342 HIV-1 infections per 100 PY (95% CI 0.191 to 0.564) (met)

Result source: NCT02842086

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEtravirineTenofovir alafenamide/​emtricitabine
HIV-1 RNA below 50 copies/mL (week 48)56% vs 39%a+17 vs placebowk 24NCT0025404693.4% vs 97.8%vs ABC/3TC+3rd Agentwk 24 · n 183NCT02605954
31 other results
  • 94.3% vs 93% wk 48 · n 333 · Phase 3 · primary NCT02121795
  • 88.6% vs 92.4% wk 48 · n 280 · Phase 3 · primary NCT02469246
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 92.4% vs 93% wk 48 · n 314 · Phase 3 · primary NCT02607930
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 96.6% vs 97.8% wk 24 · n 89 · Phase 3 · primary NCT02605954
  • 93.3% vs 91.1% wk 48 · n 284 · Phase 3 · secondary NCT03110380
  • 88.6% vs 89.1% wk 96 · n 333 · Phase 3 · secondary NCT02121795
  • 82.1% vs 88.4% wk 96 · n 280 · Phase 3 · secondary NCT02469246
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 87.9% vs 89.8% wk 96 · n 314 · Phase 3 · secondary NCT02607930
  • 81.5% vs 84.1% wk 144 · n 314 · Phase 3 · secondary NCT02607930
  • 96.9% vs 93.9% wk 24 · n 65 · Phase 2 · primary NCT02397694
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 74.8% vs 74% wk 24 · n 103 · Phase 2 · primary NCT01565850
  • 90.4% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 84.9% vs 92% wk 54 · n 53 · Phase 2 · primary NCT04143594
  • 84.6% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
  • 92.5% vs 100% wk 28 · n 53 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
  • 90.4% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 88.7% vs 96% wk 38 · n 53 · Phase 2 · secondary NCT04143594
  • 88.5% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 96.9% vs 90.9% wk 48 · n 65 · Phase 2 · secondary NCT02397694
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 76.7% vs 84% wk 48 · n 103 · Phase 2 · secondary NCT01565850
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 75.5% vs 92% wk 80 · n 53 · Phase 2 · secondary NCT04143594
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
HIV-1 RNA 50 copies/mL or more (week 48)—Not posted · NCT002550990.4% vs 1.1%vs DTG + F/TAFwk 48 · n 284NCT03110380
2 other results
  • 2.5% vs 1.1% wk 96 · n 280 · Phase 3 · secondary NCT02469246
  • 1.8% vs 0.7% wk 48 · n 280 · Phase 3 · secondary NCT02469246
CD4 count, change (week 48)—Not posted · NCT0025509960 vs 42vs Baseline Treatment Regimen (SBR)wk 96 · n 959NCT01815736
36 other results
  • 278 vs 289 wk 144 · n 262 · Phase 3 · secondary NCT02607956
  • 299 vs 317 wk 144 · n 255 · Phase 3 · secondary NCT02607930
  • 50 vs 46 wk 96 · n 299 · Phase 3 · secondary NCT02121795
  • -29 vs 10 wk 96 · n 229 · Phase 3 · secondary NCT02469246
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 237 vs 281 wk 96 · n 269 · Phase 3 · secondary NCT02607956
  • 287 vs 288 wk 96 · n 276 · Phase 3 · secondary NCT02607930
  • 20 vs 21 wk 48 · n 313 · Phase 3 · secondary NCT02121795
  • -30 vs 2 wk 48 · n 249 · Phase 3 · secondary NCT02469246
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 180 vs 201 wk 48 · n 290 · Phase 3 · secondary NCT02607956
  • 235 vs 228 wk 48 · n 294 · Phase 3 · secondary NCT02607930
  • 18 vs 36 wk 48 · n 262 · Phase 3 · secondary NCT03110380
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 5 vs 41 wk 48 · n 85 · Phase 3 · secondary NCT01968551
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • -28 vs 8 wk 24 · n 169 · Phase 3 · secondary NCT02605954
  • -23 vs 8 wk 24 · n 86 · Phase 3 · secondary NCT02605954
  • 23 vs 12 wk 24 · n 88 · Phase 3 · secondary NCT01968551
  • 275 vs 248 wk 80 · n 48 · Phase 2 · secondary NCT04143594
  • 262 vs 248 wk 80 · n 41 · Phase 2 · secondary NCT04143594
  • 245 vs 248 wk 80 · n 46 · Phase 2 · secondary NCT04143594
  • 204 vs 193 wk 54 · n 49 · Phase 2 · secondary NCT04143594
  • 213 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 220 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 231 vs 212 wk 48 · n 85 · Phase 2 · secondary NCT01565850
  • 195 vs 232 wk 38 · n 49 · Phase 2 · secondary NCT04143594
  • 220 vs 232 wk 38 · n 51 · Phase 2 · secondary NCT04143594
  • 211 vs 232 wk 38 · n 46 · Phase 2 · secondary NCT04143594
  • 172 vs 163 wk 28 · n 49 · Phase 2 · secondary NCT04143594
  • 158 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 206 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 186 vs 139 wk 24 · n 91 · Phase 2 · secondary NCT01565850

HIV-1 RNA below 50 copies/mL (week 48)

Etravirine
56% vs 39%a+17 vs placebowk 24NCT00254046
Tenofovir alafenamide/​emtricitabine
93.4% vs 97.8%vs ABC/3TC+3rd Agentwk 24 · n 183NCT02605954
31 other results
  • 94.3% vs 93% wk 48 · n 333 · Phase 3 · primary NCT02121795
  • 88.6% vs 92.4% wk 48 · n 280 · Phase 3 · primary NCT02469246
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 92.4% vs 93% wk 48 · n 314 · Phase 3 · primary NCT02607930
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 96.6% vs 97.8% wk 24 · n 89 · Phase 3 · primary NCT02605954
  • 93.3% vs 91.1% wk 48 · n 284 · Phase 3 · secondary NCT03110380
  • 88.6% vs 89.1% wk 96 · n 333 · Phase 3 · secondary NCT02121795
  • 82.1% vs 88.4% wk 96 · n 280 · Phase 3 · secondary NCT02469246
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 87.9% vs 89.8% wk 96 · n 314 · Phase 3 · secondary NCT02607930
  • 81.5% vs 84.1% wk 144 · n 314 · Phase 3 · secondary NCT02607930
  • 96.9% vs 93.9% wk 24 · n 65 · Phase 2 · primary NCT02397694
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 74.8% vs 74% wk 24 · n 103 · Phase 2 · primary NCT01565850
  • 90.4% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 84.9% vs 92% wk 54 · n 53 · Phase 2 · primary NCT04143594
  • 84.6% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
  • 92.5% vs 100% wk 28 · n 53 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
  • 90.4% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 88.7% vs 96% wk 38 · n 53 · Phase 2 · secondary NCT04143594
  • 88.5% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 96.9% vs 90.9% wk 48 · n 65 · Phase 2 · secondary NCT02397694
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 76.7% vs 84% wk 48 · n 103 · Phase 2 · secondary NCT01565850
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 75.5% vs 92% wk 80 · n 53 · Phase 2 · secondary NCT04143594
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594

HIV-1 RNA 50 copies/mL or more (week 48)

Etravirine
—Not posted · NCT00255099
Tenofovir alafenamide/​emtricitabine
0.4% vs 1.1%vs DTG + F/TAFwk 48 · n 284NCT03110380
2 other results
  • 2.5% vs 1.1% wk 96 · n 280 · Phase 3 · secondary NCT02469246
  • 1.8% vs 0.7% wk 48 · n 280 · Phase 3 · secondary NCT02469246

CD4 count, change (week 48)

Etravirine
—Not posted · NCT00255099
Tenofovir alafenamide/​emtricitabine
60 vs 42vs Baseline Treatment Regimen (SBR)wk 96 · n 959NCT01815736
36 other results
  • 278 vs 289 wk 144 · n 262 · Phase 3 · secondary NCT02607956
  • 299 vs 317 wk 144 · n 255 · Phase 3 · secondary NCT02607930
  • 50 vs 46 wk 96 · n 299 · Phase 3 · secondary NCT02121795
  • -29 vs 10 wk 96 · n 229 · Phase 3 · secondary NCT02469246
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 237 vs 281 wk 96 · n 269 · Phase 3 · secondary NCT02607956
  • 287 vs 288 wk 96 · n 276 · Phase 3 · secondary NCT02607930
  • 20 vs 21 wk 48 · n 313 · Phase 3 · secondary NCT02121795
  • -30 vs 2 wk 48 · n 249 · Phase 3 · secondary NCT02469246
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 180 vs 201 wk 48 · n 290 · Phase 3 · secondary NCT02607956
  • 235 vs 228 wk 48 · n 294 · Phase 3 · secondary NCT02607930
  • 18 vs 36 wk 48 · n 262 · Phase 3 · secondary NCT03110380
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 5 vs 41 wk 48 · n 85 · Phase 3 · secondary NCT01968551
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • -28 vs 8 wk 24 · n 169 · Phase 3 · secondary NCT02605954
  • -23 vs 8 wk 24 · n 86 · Phase 3 · secondary NCT02605954
  • 23 vs 12 wk 24 · n 88 · Phase 3 · secondary NCT01968551
  • 275 vs 248 wk 80 · n 48 · Phase 2 · secondary NCT04143594
  • 262 vs 248 wk 80 · n 41 · Phase 2 · secondary NCT04143594
  • 245 vs 248 wk 80 · n 46 · Phase 2 · secondary NCT04143594
  • 204 vs 193 wk 54 · n 49 · Phase 2 · secondary NCT04143594
  • 213 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 220 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 231 vs 212 wk 48 · n 85 · Phase 2 · secondary NCT01565850
  • 195 vs 232 wk 38 · n 49 · Phase 2 · secondary NCT04143594
  • 220 vs 232 wk 38 · n 51 · Phase 2 · secondary NCT04143594
  • 211 vs 232 wk 38 · n 46 · Phase 2 · secondary NCT04143594
  • 172 vs 163 wk 28 · n 49 · Phase 2 · secondary NCT04143594
  • 158 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 206 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 186 vs 139 wk 24 · n 91 · Phase 2 · secondary NCT01565850
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety

Coverage. Etravirine: 10 of 10 rows · Tenofovir alafenamide/emtricitabine: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEtravirine
Rows use multiple source trials
Tenofovir alafenamide/​emtricitabine
Rows use multiple source trials
CD4
absolute change · count
Induction
143.24 vs 151.46 Efavirenz count @ 12wka,b
NCT00903682 · Phase 2 · registry result, not featured evidence
170 vs 173 DTG + F/TAF count @ 12wka,b
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
CD4
absolute change · count
Maintenance
205.11 vs 221.39 Efavirenz count @ 48wka,b
NCT00903682 · Phase 2 · registry result, not featured evidence
258 vs 188 DTG + F/TAF count @ 48wka,b
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
CD4+
absolute change · cells/uL
No placebo or comparator arm
163 cells/uL @ 48wk400 mg once dailyc,a,b
NCT00959894 · Phase 2 · registry result, not featured evidence
2 other source trials
156 cells/uL @ 48wk
NCT00665847 · Phase 2 · registry result, not featured evidence
21.5 cells/uL @ 48wk
NCT00128830 · Phase 2 · registry result, not featured evidence
224 cells/uL @ 48wkd,c,a,b
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
show 2 more doses
-66 cells/uL @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
-179 cells/uL @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
HIV-1 RNA
absolute change · copies/mL
No placebo or comparator arm
-1.4 copies/mL @ 48wk400/100 mgd,c,a
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
-1.4 copies/mL @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-3.26 copies/mL @ 48wkc,a
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
HIV-1 RNA
absolute change · log
No placebo or comparator arm
-1.53 log @ 48wke,a,b
NCT00665847 · Phase 2 · registry result, not featured evidence
-3.04 log @ 48wke,a,b
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
HIV-1 RNA Less Than 50 Copies
responder rate · % of participants
No placebo or comparator arm
45.5% (n=22) @ 48wk400/100 mgd,e,a,b
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
50% (n=22) @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
93% (n=242) @ 48wkd,e,a,b
NCT01818596 · Phase 3
show 1 more dose
100% (n=6) @ 48wk
NCT01818596 · Phase 3
Dropout rate
n/a: no completion milestonef
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
20.3%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
36%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
40%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
24.8%
NCT00665847 · Phase 2 · registry result, not featured evidence
20.3%
NCT00903682 · Phase 2 · registry result, not featured evidence
34.1%
NCT00128830 · Phase 2 · registry result, not featured evidence
5%Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
16.7%Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
—200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
17.9%
NCT00871234 · Phase 1 · registry result, not featured evidence
0%
NCT01625169 · Phase na · registry result, not featured evidence · combination
—
NCT01427504 · Phase na · registry result, not featured evidence · combination
11.4%F/TAF + 3rd Agentg
NCT02121795 · Phase 3 · combination
show 52 more results
—F/TAF + 3rd Agent (Double-Blind)
NCT02121795 · Phase 3 · combination
—Open-Label F/TAF From F/TAF
NCT02121795 · Phase 3
—Open-Label F/TAF From FTC/TDF
NCT02121795 · Phase 3
23.5%F/TAF
NCT02469246 · Phase 3
—F/TAF (Double-Blind Phase)
NCT02469246 · Phase 3
—Open-Label F/TAF From ABC/3TC
NCT02469246 · Phase 3
—Open-Label F/TAF From F/TAF
NCT02469246 · Phase 3
20%E/C/F/TAF
NCT01797445 · Phase 3
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3
5.1%E/C/F/TAF
NCT01815736 · Phase 3
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3
12.6%Cohort 1 (Treatment-experienced)
NCT01818596 · Phase 3
0%Cohort 2 (Treatment-naive)
NCT01818596 · Phase 3
4%Cohort 1: Age 12 to < 18 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
1.9%Cohort 2: Age 6 to < 12 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
0%Cohort 3: Age ≥ 2 Years and Weight
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
4.4%
NCT04782180 · Phase 4 · registry result, not featured evidence
18.7%
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
17.1%B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
7.4%B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
—Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3 · registry result, not featured evidence
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence · combination
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
5.4%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Delayed E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
6.6%E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
5.3%E/C/F/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
5.4%F/R/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
0%Part 1 Randomized Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
0%Part 1 Sentinel Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
—Part 2 E/C/F/TAF + ATV
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
—HIV-Suppressed
NCT02071082 · Phase 3 · registry result, not featured evidence
—HIV/HBV Treatment-Naive
NCT02071082 · Phase 3 · registry result, not featured evidence
9.1%Cohort 1: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
3.3%Cohort 2: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
8%E/C/F/TAF (12 - 17 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
0%E/C/F/TAF (≥ 18 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
21.2%Group 1: SC LEN+(F/TAF→ TAF)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
34%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
30.8%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
4.6%BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
5.3%
NCT01497899 · Phase 2 · registry result, not featured evidence
19.4%
NCT01565850 · Phase 2 · registry result, not featured evidence
3%
NCT03960645 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
6.7%f
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
3.8%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
4%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
8%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
7.9%
NCT00665847 · Phase 2 · registry result, not featured evidence
7.6%
NCT00903682 · Phase 2 · registry result, not featured evidence
4.7%
NCT00128830 · Phase 2 · registry result, not featured evidence
—Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
—200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
7.1%
NCT00871234 · Phase 1 · registry result, not featured evidence
—
NCT01625169 · Phase na · registry result, not featured evidence · combination
—
NCT01427504 · Phase na · registry result, not featured evidence · combination
1.5%F/TAF + 3rd Agentg
NCT02121795 · Phase 3 · combination
show 52 more results
—F/TAF + 3rd Agent (Double-Blind)
NCT02121795 · Phase 3 · combination
—Open-Label F/TAF From F/TAF
NCT02121795 · Phase 3
—Open-Label F/TAF From FTC/TDF
NCT02121795 · Phase 3
4.2%F/TAF
NCT02469246 · Phase 3
—F/TAF (Double-Blind Phase)
NCT02469246 · Phase 3
—Open-Label F/TAF From ABC/3TC
NCT02469246 · Phase 3
—Open-Label F/TAF From F/TAF
NCT02469246 · Phase 3
0.7%E/C/F/TAF
NCT01797445 · Phase 3
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3
0.7%E/C/F/TAF
NCT01815736 · Phase 3
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3
2.8%Cohort 1 (Treatment-experienced)
NCT01818596 · Phase 3
0%Cohort 2 (Treatment-naive)
NCT01818596 · Phase 3
—Cohort 1: Age 12 to < 18 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
—Cohort 2: Age 6 to < 12 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
—Cohort 3: Age ≥ 2 Years and Weight
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
—
NCT04782180 · Phase 4 · registry result, not featured evidence
1.2%
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0%B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
1.1%B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
—Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3 · registry result, not featured evidence
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence · combination
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
0.9%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Delayed E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
2.7%E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
—F/R/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
—Part 1 Randomized Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
—Part 1 Sentinel Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
—Part 2 E/C/F/TAF + ATV
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
—HIV-Suppressed
NCT02071082 · Phase 3 · registry result, not featured evidence
—HIV/HBV Treatment-Naive
NCT02071082 · Phase 3 · registry result, not featured evidence
—Cohort 1: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
—Cohort 2: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
—E/C/F/TAF (12 - 17 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
—E/C/F/TAF (≥ 18 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
1.9%Group 1: SC LEN+(F/TAF→ TAF)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
0%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
0%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
1.5%BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
0.9%
NCT01497899 · Phase 2 · registry result, not featured evidence
0%
NCT01565850 · Phase 2 · registry result, not featured evidence
—
NCT03960645 · Phase 1 · registry result, not featured evidence
Serious AEs
10%f
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
15.2%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
8%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
16%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
5%
NCT00665847 · Phase 2 · registry result, not featured evidence
13.9%
NCT00903682 · Phase 2 · registry result, not featured evidence
21.8%
NCT00128830 · Phase 2 · registry result, not featured evidence
25%Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
50%Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
0%200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
0%200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
0%
NCT00871234 · Phase 1 · registry result, not featured evidence
0%
NCT01625169 · Phase na · registry result, not featured evidence · combination
20%
NCT01427504 · Phase na · registry result, not featured evidence · combination
—F/TAF + 3rd Agentg
NCT02121795 · Phase 3 · combination
show 52 more results
8.7%F/TAF + 3rd Agent (Double-Blind)
NCT02121795 · Phase 3 · combination
6.1%Open-Label F/TAF From F/TAF
NCT02121795 · Phase 3
9.7%Open-Label F/TAF From FTC/TDF
NCT02121795 · Phase 3
—F/TAF
NCT02469246 · Phase 3
19.6%F/TAF (Double-Blind Phase)
NCT02469246 · Phase 3
0%Open-Label F/TAF From ABC/3TC
NCT02469246 · Phase 3
0%Open-Label F/TAF From F/TAF
NCT02469246 · Phase 3
—E/C/F/TAF
NCT01797445 · Phase 3
12.5%E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3
2.8%Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3
1.7%Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3
—E/C/F/TAF
NCT01815736 · Phase 3
3%Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3
5.2%Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3
8.2%Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3
22.7%Cohort 1 (Treatment-experienced)
NCT01818596 · Phase 3
16.7%Cohort 2 (Treatment-naive)
NCT01818596 · Phase 3
20%Cohort 1: Age 12 to < 18 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
13.5%Cohort 2: Age 6 to < 12 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
3.7%Cohort 3: Age ≥ 2 Years and Weight
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
0%
NCT04782180 · Phase 4 · registry result, not featured evidence
20%
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
14%B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
7.5%B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
12.7%Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3 · registry result, not featured evidence
9.6%Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
9.5%Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence · combination
5.3%DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
8.7%Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
9.1%
NCT02616783 · Phase 3 · registry result, not featured evidence
4.5%Delayed E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
6.6%E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
9.5%E/C/F/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
16.2%F/R/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
10.7%Part 1 Randomized Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
0%Part 1 Sentinel Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
10.8%Part 2 E/C/F/TAF + ATV
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
16.2%HIV-Suppressed
NCT02071082 · Phase 3 · registry result, not featured evidence
0%HIV/HBV Treatment-Naive
NCT02071082 · Phase 3 · registry result, not featured evidence
4.8%Cohort 1: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
10.1%Cohort 2: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
6%E/C/F/TAF (12 - 17 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
0%E/C/F/TAF (≥ 18 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
7.7%Group 1: SC LEN+(F/TAF→ TAF)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
7.5%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
13.5%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
6.2%BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
10.7%
NCT01497899 · Phase 2 · registry result, not featured evidence
4.9%
NCT01565850 · Phase 2 · registry result, not featured evidence
18.2%
NCT03960645 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
f
cough 2.8%
upper respiratory tract infection 2.8%
pregnancy 2.2%
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
400 mg once daily
elevated level of transaminase 11.4%
hyperbilirubinemia 7.6%
hyperlipidemia 7.6%
NCT00959894 · Phase 2 · registry result, not featured evidence
400/100 mg
cough 16%
headache 12%
influenza 12%
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
300/100 mg
cough 20%
nausea 16%
blood bilirubin increased 12%
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
upper respiratory tract infection 26.7%
diarrhoea 15.8%
cough 12.9%
NCT00665847 · Phase 2 · registry result, not featured evidence
nasopharyngitis 21.5%
headache 16.5%
diarrhoea 10.1%
NCT00903682 · Phase 2 · registry result, not featured evidence
diarrhoea 17.5%
upper respiratory tract infection 17.1%
sinusitis 11.4%
NCT00128830 · Phase 2 · registry result, not featured evidence
blood bicarbonate decreased 90%
blood sodium decreased 70%
nasal congestion 70%
NCT01504841 · Phase 1/2 · registry result, not featured evidence
cough 100%
nasal congestion 100%
rhinorrhoea 100%
NCT01504841 · Phase 1/2 · registry result, not featured evidence
200 mg + 200 mg
headache 18.8%
toothache 12.5%
diarrhoea 6.3%
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
200 mg + 600/100 mg + 200 mg
rash maculo-papular 20%
scleral hyperaemia 20%
headache 13.3%
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
headache 14.3%
constipation 10.7%
diarrhea 7.1%
NCT00871234 · Phase 1 · registry result, not featured evidence
breast tenderness 66.7%
diarrhea 11.1%
headache 11.1%
NCT01625169 · Phase na · registry result, not featured evidence · combination
altered taste 64%
headache 16%
rash 16%
NCT01427504 · Phase na · registry result, not featured evidence · combination
g
upper respiratory tract infection 16.2%
diarrhoea 13.2%
nasopharyngitis 12.9%
NCT02121795 · Phase 3 · combination
show 45 more results
nasopharyngitis 12.1%
back pain 9.1%
syphilis 9.1%
NCT02121795 · Phase 3
onychomycosis 9.7%
sinusitis 9.7%
arthralgia 6.5%
NCT02121795 · Phase 3
nasopharyngitis 20.4%
upper respiratory tract infection 12.9%
cough 12.1%
NCT02469246 · Phase 3
nasopharyngitis 20%
renal colic 20%
rhinitis 20%
NCT02469246 · Phase 3
spinal pain 16.7%
arthralgia 0%
back pain 0%
NCT02469246 · Phase 3
diarrhoea 23%
headache 22.7%
upper respiratory tract infection 20.2%
NCT01797445 · Phase 3
nasopharyngitis 3.5%
headache 2.8%
arthralgia 1.4%
NCT01797445 · Phase 3
nasopharyngitis 4.2%
cough 2.5%
syphilis 2.5%
NCT01797445 · Phase 3
upper respiratory tract infection 7.4%
nasopharyngitis 5.2%
diarrhoea 4.4%
NCT01815736 · Phase 3
upper respiratory tract infection 6.1%
diarrhoea 5.2%
nasopharyngitis 4.7%
NCT01815736 · Phase 3
upper respiratory tract infection 17.5%
diarrhoea 11.4%
nasopharyngitis 10%
NCT01815736 · Phase 3
upper respiratory tract infection 16.1%
bronchitis 15.3%
arthralgia 14%
NCT01818596 · Phase 3
hyperlipidaemia 33.3%
pain in extremity 33.3%
anogenital warts 16.7%
NCT01818596 · Phase 3
upper respiratory tract infection 40%
respiratory tract infection 38%
nausea 30%
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
upper respiratory tract infection 26.9%
vomiting 25%
respiratory tract infection 21.2%
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
upper respiratory tract infection 51.9%
cough 33.3%
nasopharyngitis 18.5%
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
diarrhoea 20.6%
headache 17.8%
nasopharyngitis 15.9%
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
diarrhoea 17.2%
upper respiratory tract infection 14.6%
headache 14%
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
syphilis 8.7%
covid-19 7.9%
nasopharyngitis 7.1%
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
nasopharyngitis 15.5%
upper respiratory tract infection 11.6%
diarrhoea 9.2%
NCT03110380 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 7.2%
arthralgia 3.2%
bronchitis 3.2%
NCT03110380 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 8.6%
diarrhoea 6%
fatigue 6%
NCT03110380 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 14.6%
headache 11%
anaemia 7.3%
NCT01705574 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.3%
headache 17%
nausea 14.9%
NCT01705574 · Phase 3 · registry result, not featured evidence
nasopharyngitis 10.9%
back pain 8.2%
diarrhoea 7.3%
NCT02616783 · Phase 3 · registry result, not featured evidence
arthralgia 9%
diarrhoea 4.5%
headache 4.5%
NCT02605954 · Phase 3 · registry result, not featured evidence
diarrhoea 10.4%
headache 8.2%
vitamin d deficiency 7.1%
NCT02605954 · Phase 3 · registry result, not featured evidence
urinary tract infection 13.5%
upper respiratory tract infection 12.2%
arthralgia 9.5%
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
cough 13.5%
headache 10.8%
nausea 8.1%
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
hyperbilirubinaemia 3.6% (placebo 0%)
influenza 3.6% (placebo 0%)
jaundice 3.6% (placebo 0%)
NCT01967940 · Phase 3 · registry result, not featured evidence
nausea 16.7% (placebo 0%)
arthralgia 8.3% (placebo 0%)
diarrhoea 8.3% (placebo 0%)
NCT01967940 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 29.7% (placebo 0%)
malaria 13.5% (placebo 0%)
headache 10.8% (placebo 0%)
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 23%
nasopharyngitis 12.2%
diarrhoea 10.8%
NCT02071082 · Phase 3 · registry result, not featured evidence
dental caries 33.3%
diarrhoea 33.3%
herpes zoster 33.3%
NCT02071082 · Phase 3 · registry result, not featured evidence
acute sinusitis 19%
bronchitis 14.3%
sinusitis 14.3%
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
back pain 12.4%
upper respiratory tract infection 11.2%
bronchitis 6.7%
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
cough 24%
upper respiratory tract infection 22%
vomiting 16%
NCT02276612 · Phase 2/3 · registry result, not featured evidence
upper respiratory tract infection 60%
cough 50%
nasal obstruction 30%
NCT02276612 · Phase 2/3 · registry result, not featured evidence
injection site erythema 48.1%
injection site swelling 32.7%
injection site pain 28.8%
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
injection site erythema 34%
injection site swelling 34%
injection site pain 26.4%
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
covid-19 21.2%
influenza 21.2%
headache 17.3%
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 13.8%
upper respiratory tract infection 10.8%
headache 9.2%
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
nausea 22.3%
diarrhoea 17%
fatigue 16.1%
NCT01497899 · Phase 2 · registry result, not featured evidence
diarrhoea 21.4%
upper respiratory tract infection 15.5%
fatigue 13.6%
NCT01565850 · Phase 2 · registry result, not featured evidence
back pain 12.1%
gestational diabetes 12.1%
anaemia 9.1%
NCT03960645 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cTrial phases differ: Phase 2 versus Phase 2/3.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 2 versus Phase 3.
  6. fPopulation comparability has not been reviewed for these studies.
  7. gPopulation comparability has not been reviewed for 47 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Etravirine

HIV-1 RNA Less Than 50 Copies 0.87% (n=79) @ 24wk400 mg once daily
event count · % of participants
No placebo or comparator arm
NCT00959894 · Phase 2 · registry result, not featured evidence
show 2 more results
0.77% (n=79) @ 48wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
0.71% (n=79) @ 96wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
HIV-1 RNA LT 200 Copies 0.89% (n=79) @ 24wk400 mg once daily
event count · % of participants
No placebo or comparator arm
NCT00959894 · Phase 2 · registry result, not featured evidence
show 2 more results
0.82% (n=79) @ 48wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
0.77% (n=79) @ 96wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
CD4 46 count @ 4wk400/100 mg
absolute change · count
No placebo or comparator arm
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 7 more results
72 count @ 12wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
83 count @ 24wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
132 count @ 48wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
55 count @ 4wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
31 count @ 12wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
54 count @ 24wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
105 count @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
Virological Response 50 Copies Snapshot 45.5% (n=22) @ 48wk400/100 mg
responder rate · % of participants
No placebo or comparator arm
Virologic Response
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
50% (n=22) @ 48wk300/100 mg
Virologic Response
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
Time to Viral Suppression 2.5 months400/100 mg
time to event · months
No placebo or comparator arm
Plasma VL < 50 copies/mL
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 76 days as posted
show 1 more result
2.33 months*300/100 mg
Plasma VL < 50 copies/mL
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 71 days as posted
Time to Virologic Failure NA months400/100 mg
time to event · months
No placebo or comparator arm
Virologic Responders (Plasma VL < 50 copies/mL)
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
10.45 months*300/100 mg
Virologic Responders (Plasma VL < 50 copies/mL)
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 318 days as posted
Virologic 52.5% (n=101) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT00665847 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 400 Copies Per 75.9% (n=79) vs 74.4% (n=78) Efavirenz @ 48wk
event count · % of participants
NCT00903682 · Phase 2 · registry result, not featured evidence · converted to % from 60 Number of participants as posted
show 1 more result
81% (n=79) vs 79.5% (n=78) Efavirenz @ 48wk*
NCT00903682 · Phase 2 · registry result, not featured evidence · converted to % from 64 Number of participants as posted
HIV-1 RNA Less Than 50 Copies 58% (n=181) @ 96wk
responder rate · % of participants
No placebo or comparator arm
Viral load (VL) less than 50 copies/mL
NCT00128830 · Phase 2 · registry result, not featured evidence · converted to % from 105 Participants as posted
show 1 more result
70.4% (n=98) @ 192wk*
Viral load (VL) less than 50 copies/mL
NCT00128830 · Phase 2 · registry result, not featured evidence · converted to % from 69 Participants as posted
HIV-1 RNA Less Than 400 Copies 68.5% (n=181) @ 96wk
responder rate · % of participants
No placebo or comparator arm
Viral load less than 400 copies/mL
NCT00128830 · Phase 2 · registry result, not featured evidence · converted to % from 124 Participants as posted
HIV-1 RNA Less Than 400 Copies 82.7% (n=98) @ 192wk
responder rate · % of participants
No placebo or comparator arm
VL less than 400 copies/mL
NCT00128830 · Phase 2 · registry result, not featured evidence · converted to % from 81 Participants as posted
Virologic Failure 18.2% (n=11) @ 24wk
event count · % of participants
No placebo or comparator arm
Week 24 · Virologic Failure
NCT01504841 · Phase 1/2 · registry result, not featured evidence · converted to % from 2 Participants as posted
show 1 more result
25% (n=4) @ 24wk*
Week 24 · Virologic Failure
NCT01504841 · Phase 1/2 · registry result, not featured evidence · converted to % from 1 Participants as posted

+ 3 further endpoints in the CSV export.

Tenofovir alafenamide/emtricitabine

HIV-1 RNA Less Than 20 Copies 91.6% (n=333) vs 90.9% (n=330) FTC/TDF @ 48wk
responder rate · % of participants
NCT02121795 · Phase 3 · combination
show 6 more results
83.5% (n=333) vs 86.1% (n=330) FTC/TDF @ 96wk
NCT02121795 · Phase 3 · combination
85.7% (n=280) vs 87.3% (n=276) ABC/3TC @ 48wk
NCT02469246 · Phase 3
80.4% (n=280) vs 86.2% (n=276) ABC/3TC @ 96wk
NCT02469246 · Phase 3
82.4% (n=431) vs 80.7% (n=435) E/C/F/TDF @ 48wk
NCT01797445 · Phase 3
78.7% (n=431) vs 76.8% (n=435) E/C/F/TDF @ 96wk
NCT01797445 · Phase 3
90.6% (n=959) vs 85.3% (n=477) Baseline Treatment Regimen (SBR) @ 96wk
NCT01815736 · Phase 3
CD4+ 20 vs 21 FTC/TDF cells/uL @ 48wk
absolute change · cells/uL
NCT02121795 · Phase 3 · combination
show 36 more results
50 vs 46 FTC/TDF cells/uL @ 96wk
NCT02121795 · Phase 3 · combination
-30 vs 2 ABC/3TC cells/uL @ 48wk
NCT02469246 · Phase 3
-29 vs 10 ABC/3TC cells/uL @ 96wk
NCT02469246 · Phase 3
225 vs 200 E/C/F/TDF cells/uL @ 48wk
NCT01797445 · Phase 3
274 vs 260 E/C/F/TDF cells/uL @ 96wk
NCT01797445 · Phase 3
60 vs 42 Baseline Treatment Regimen (SBR) cells/uL @ 96wk
NCT01815736 · Phase 3
180 vs 201 DTG + F/TAF cells/uL @ 48wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
237 vs 281 DTG + F/TAF cells/uL @ 96wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
278 vs 289 DTG + F/TAF cells/uL @ 144wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
235 vs 228 ABC/DTG/3TC cells/uL @ 48wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
287 vs 288 ABC/DTG/3TC cells/uL @ 96wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
299 vs 317 ABC/DTG/3TC cells/uL @ 144wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
18 vs 36 DTG + F/TAF cells/uL @ 48wk
NCT03110380 · Phase 3 · registry result, not featured evidence
221 vs 212 ATV+RTV+TVD cells/uL @ 48wk
NCT01705574 · Phase 3 · registry result, not featured evidence
48 vs -4 Stay on Baseline Regimen cells/uL @ 24wk
NCT02616783 · Phase 3 · registry result, not featured evidence
56 vs -1 Stay on Baseline Regimen cells/uL @ 48wk
NCT02616783 · Phase 3 · registry result, not featured evidence
-28 vs 8 ABC/3TC+3rd Agent cells/uL @ 24wk
NCT02605954 · Phase 3 · registry result, not featured evidence
-23 vs 8 ABC/3TC+3rd Agent cells/uL @ 24wk
NCT02605954 · Phase 3 · registry result, not featured evidence
23 vs 12 SBR cells/uL @ 24wk
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
5 vs 41 SBR cells/uL @ 48wk
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
172 vs 163 B/F/TAF cells/uL @ 28wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
158 vs 163 B/F/TAF cells/uL @ 28wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
206 vs 163 B/F/TAF cells/uL @ 28wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
195 vs 232 B/F/TAF cells/uL @ 38wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
220 vs 232 B/F/TAF cells/uL @ 38wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
211 vs 232 B/F/TAF cells/uL @ 38wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
204 vs 193 B/F/TAF cells/uL @ 54wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
213 vs 193 B/F/TAF cells/uL @ 54wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
220 vs 193 B/F/TAF cells/uL @ 54wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
275 vs 248 B/F/TAF cells/uL @ 80wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
262 vs 248 B/F/TAF cells/uL @ 80wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
245 vs 248 B/F/TAF cells/uL @ 80wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
165 vs 179 E/C/F/TDF cells/uL @ 24wk
NCT01497899 · Phase 2 · registry result, not featured evidence
177 vs 204 E/C/F/TDF cells/uL @ 48wk
NCT01497899 · Phase 2 · registry result, not featured evidence
186 vs 139 DRV+COBI+FTC/TDF cells/uL @ 24wk
NCT01565850 · Phase 2 · registry result, not featured evidence
231 vs 212 DRV+COBI+FTC/TDF cells/uL @ 48wk
NCT01565850 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Ge50 Copies 1.8% (n=280) vs 0.7% (n=276) ABC/3TC @ 48wk
responder rate · % of participants
NCT02469246 · Phase 3
show 2 more results
2.5% (n=280) vs 1.1% (n=276) ABC/3TC @ 96wk
NCT02469246 · Phase 3
0.4% (n=284) vs 1.1% (n=281) DTG + F/TAF @ 48wk
NCT03110380 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 97.2% (n=959) vs 93.1% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
All Participants
NCT01815736 · Phase 3
HIV-1 RNA Less Than 20 Copies 93.5% (n=959) vs 90.4% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
All Participants
NCT01815736 · Phase 3
HIV-1 RNA Less 400 94% (n=50) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
show 9 more results
94% (n=50) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
94% (n=50) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
94% (n=50) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
97.9% (n=48) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
97.9% (n=48) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
CD4+ 7.7% (n=50) @ 24wk
absolute change · percentage points
No placebo or comparator arm
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
show 5 more results
9.3% (n=50) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
-0.8% (n=52) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
-0.6% (n=52) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
0% (n=27) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
0.2% (n=27) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
HIV RNA Less Than 50 Copies 89.4% (n=320) vs 92.9% (n=325) DTG + F/TAF @ 48wk
responder rate · % of participants
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
show 2 more results
84.1% (n=320) vs 86.5% (n=325) DTG + F/TAF @ 96wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
81.9% (n=320) vs 84% (n=325) DTG + F/TAF @ 144wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
HIV-1 RNA Less Than 20 82.2% (n=320) vs 87.1% (n=325) DTG + F/TAF @ 48wk
responder rate · % of participants
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
show 5 more results
77.5% (n=320) vs 80.3% (n=325) DTG + F/TAF @ 96wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
77.5% (n=320) vs 79.1% (n=325) DTG + F/TAF @ 144wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
87.6% (n=314) vs 87.3% (n=315) ABC/DTG/3TC @ 48wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
83.4% (n=314) vs 84.8% (n=315) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
78% (n=314) vs 82.2% (n=315) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
HIV-1 RNA -3.07 vs -3.12 DTG + F/TAF log @ 48wk
absolute change · log
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
show 26 more results
-3.08 vs -3.1 DTG + F/TAF log @ 96wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
-3.06 vs -3.11 DTG + F/TAF log @ 144wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
-3.11 vs -3.07 ABC/DTG/3TC log @ 48wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
-3.09 vs -3.1 ABC/DTG/3TC log @ 96wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
-3.11 vs -3.1 ABC/DTG/3TC log @ 144wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
-0.72 vs -0.04 placebo log @ 1.428571wk
NCT01967940 · Phase 3 · registry result, not featured evidence
-0.7 vs -0.04 placebo log @ 1.428571wk
NCT01967940 · Phase 3 · registry result, not featured evidence
-2.92 vs -3.07 B/F/TAF log @ 28wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-3.04 vs -3.07 B/F/TAF log @ 28wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-3.01 vs -3.07 B/F/TAF log @ 28wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-2.96 vs -3.04 B/F/TAF log @ 38wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-3.06 vs -3.04 B/F/TAF log @ 38wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-3.02 vs -3.04 B/F/TAF log @ 38wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-2.95 vs -3.08 B/F/TAF log @ 54wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-3.12 vs -3.08 B/F/TAF log @ 54wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-2.85 vs -3.08 B/F/TAF log @ 54wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-2.96 vs -3.09 B/F/TAF log @ 80wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-3.08 vs -3.09 B/F/TAF log @ 80wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-2.96 vs -3.09 B/F/TAF log @ 80wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-3.03 vs -3.15 DTG + F/TAF log @ 12wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
-3.09 vs -3.12 DTG + F/TAF log @ 24wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
-3.09 vs -3.11 DTG + F/TAF log @ 48wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
-3.2 vs -3.26 E/C/F/TDF log @ 24wk
NCT01497899 · Phase 2 · registry result, not featured evidence
-3.22 vs -3.33 E/C/F/TDF log @ 48wk
NCT01497899 · Phase 2 · registry result, not featured evidence
-3.2 vs -3.18 DRV+COBI+FTC/TDF log @ 24wk
NCT01565850 · Phase 2 · registry result, not featured evidence
-3.27 vs -3.26 DRV+COBI+FTC/TDF log @ 48wk
NCT01565850 · Phase 2 · registry result, not featured evidence
Hip BMD -0.802% (n=278) vs -1.148% (n=281) ABC/DTG/3TC @ 48wk
percent change · % of baseline
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
show 4 more results
-1.128% (n=250) vs -1.262% (n=257) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
-1.02% (n=236) vs -1.291% (n=240) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
1.33% (n=101) vs -0.726% (n=54) Stay on Baseline Regimen @ 48wk
NCT02616783 · Phase 3 · registry result, not featured evidence
0.808% (n=103) vs -0.537% (n=54) Stay on Baseline Regimen @ 24wk
NCT02616783 · Phase 3 · registry result, not featured evidence
Spine BMD -0.772% (n=284) vs -0.552% (n=285) ABC/DTG/3TC @ 48wk
percent change · % of baseline
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
show 2 more results
-0.705% (n=256) vs -0.219% (n=258) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
-0.371% (n=243) vs 0.035% (n=244) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3

+ 14 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Etravirine's landscape · Tenofovir alafenamide/emtricitabine's landscape